The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment
Open accessAbstract
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant condition in which susceptible individuals are at risk for the development of cutaneous leiomyomas, early onset multiple uterine leiomyomas and an aggressive form of type 2 papillary renal cell cancer. HLRCC is caused by germline mutations in the fumarate hydratase (FH) gene which inactivate the enzyme and alters the function of the tricarboxylic acid (Krebs) cycle. Issues surrounding surveillance and treatment for HLRCC-associated renal cell cancer were considered as part of a recent international symposium on HLRCC. The management protocol proposed in this article is based on a literature review and a consensus meeting. The lifetime renal cancer risk for FH mutation carriers is estimated to be 15 %. In view of the potential for early onset of RCC in HLRCC, periodic renal imaging and, when available, predictive testing for a FH mutation is recommended from 8 to 10 years of age. However, the small risk of renal cell cancer in the 10–20 years age range and the potential drawbacks of screening should be carefully discussed on an individual basis. Surveillance preferably consists of annual abdominal MRI. Treatment of renal tumours should be prompt and generally consist of wide-margin surgical excision and consideration of retroperitoneal lymph node dissection. The choice for systemic treatment in metastatic disease should, if possible, be part of a clinical trial. Screening procedures in HLRCC families should preferably be evaluated in large cohorts of families.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635
Reductive carboxylation supports growth in tumour cells with defective mitochondria
Mullen, A. R., Wheaton, W. W., Jin, E. S., Chen, P.-H., Sullivan, L. B., Cheng, T., Yang, Y., Linehan, W. M., Chandel, N. S., & DeBerardinis, R. J. (2012) · Nature · doi:10.1038/nature10642 · Cited by 1,328
Self-citationXiao, M., Yang, H., Xu, W., Ma, S., Lin, H., Zhu, H., Liu, L., Liu, Y., Yang, C., Xu, Y., et al. (2012) · Genes & Development · doi:10.1101/gad.191056.112 · Cited by 1,188
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia
Srigley, J. R., Delahunt, B., Eble, J. N., Egevad, L., Epstein, J. I., Grignon, D., Hes, O., Moch, H., Montironi, R., Tickoo, S. K., et al. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318299f2d1 · Cited by 1,047
Isaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.017 · Cited by 958
Self-citationInfluence of Metabolism on Epigenetics and Disease
Kaelin, W. G., & McKnight, S. L. (2013) · Cell · doi:10.1016/j.cell.2013.03.004 · Cited by 920
The genetic basis of kidney cancer: a metabolic disease
Linehan, W. M., Srinivasan, R., & Schmidt, L. S. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.47 · Cited by 744
Self-citationToro, J. R., Nickerson, M. L., Wei, M.-H., Warren, M. B., Glenn, G. M., Turner, M. L., Stewart, L., Duray, P., Tourre, O., Sharma, N., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/376435 · Cited by 634
Self-citationGuidelines on Renal Cell Carcinoma
Ljungberg, B., Hanbury, D. C., Kuczyk, M. A., Merseburger, A. S., Mulders, P., Patard, J., & Sinescu, I. C. (2007) · Cited by 421
Merino, M. J., Torres-Cabala, C., Pinto, P., & Marston Linehan, W. (2007) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31804375b8 · Cited by 409
Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas
Castro-Vega, L. J., Buffet, A., De Cubas, A. A., Cascón, A., Menara, M., Khalifa, E., Amar, L., Azriel, S., Bourdeau, I., Chabre, O., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt639 · Cited by 397
Systematic Review of Oncological Outcomes Following Surgical Management of Localised Renal Cancer
MacLennan, S. J., Imamura, M., Lapitan, M. C., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.02.039 · Cited by 355
Alam, N. A. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg148 · Cited by 324
Wei, M.-H., Toure, O., Glenn, G. M., Pithukpakorn, M., Neckers, L., Stolle, C., Choyke, P., Grubb, R., Middelton, L., Turner, M. L., et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.033506 · Cited by 313
Self-citationGrubb, R. L., Franks, M. E., Toro, J., Middelton, L., Choyke, L., Fowler, S., Torres-Cabala, C., Glenn, G. M., Choyke, P., Merino, M. J., et al. (2007) · Journal of Urology · doi:10.1016/j.juro.2007.01.155 · Cited by 282
Self-citationBardella, C., El‐Bahrawy, M., Frizzell, N., Adam, J., Ternette, N., Hatipoglu, E., Howarth, K., O'Flaherty, L., Roberts, I., Turner, G., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2932 · Cited by 281
Self-citationChen, Y.-B., Brannon, A. R., Toubaji, A., Dudas, M. E., Won, H. H., Al-Ahmadie, H. A., Fine, S. W., Gopalan, A., Frizzell, N., Voss, M. H., et al. (2014) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000163 · Cited by 276
WALTHER, M. M., CHOYKE, P. L., GLENN, G., LYNE, J. C., RAYFORD, W., VENZON, D., & LINEHAN, W. M. (1999) · Journal of Urology · doi:10.1016/s0022-5347(05)68930-6 · Cited by 249
Self-citationGenetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics
Linehan, W. M. (2012) · Genome Research · doi:10.1101/gr.131110.111 · Cited by 243
Self-citationCutaneous leiomyomata with uterine leiomyomata
Reed, W., Walker, R., & Horowitz, R. (1973) · Acta Dermato-Venereologica · doi:10.2340/0001555553409416 · Cited by 228
Increased risk of cancer in patients with fumarate hydratase germline mutation
Lehtonen, H. J., Kiuru, M., Ylisaukko-oja, S. K., Salovaara, R., Herva, R., Koivisto, P. A., Vierimaa, O., Aittomäki, K., Pukkala, E., Launonen, V, et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.036400 · Cited by 225
Self-citationLinehan, W. M., & Rouault, T. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0304 · Cited by 223
Self-citationTHE RELATIONSHIP BETWEEN RENAL TUMOR SIZE AND METASTASES IN PATIENTS WITH VON HIPPEL-LINDAU DISEASE
DUFFEY, B. G., CHOYKE, P. L., GLENN, G., GRUBB, R. L., VENZON, D., LINEHAN, W. M., & WALTHER, M. M. (2004) · Journal of Urology · doi:10.1097/01.ju.0000132127.79974.3f · Cited by 216
Self-citationTong, W.-H., Sourbier, C., Kovtunovych, G., Jeong, S. Y., Vira, M., Ghosh, M., Romero, V. V., Sougrat, R., Vaulont, S., Viollet, B., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.07.018 · Cited by 212
Clinical Features of Multiple Cutaneous and Uterine Leiomyomatosis: An Underdiagnosed Tumor Syndrome
Alam, N. A., Barclay, E., Rowan, A. J., Tyrer, J. P., Calonje, E., Manek, S., Kelsell, D., Leigh, I., Olpin, S., & Tomlinson, I. P. M. (2005) · Archives of Dermatology · doi:10.1001/archderm.141.2.199 · Cited by 197
Self-citationSmit, D., Mensenkamp, A., Badeloe, S., Breuning, M., Simon, M., Van Spaendonck, K., Aalfs, C., Post, J., Shanley, S., Krapels, I., et al. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2010.01486.x · Cited by 195
Self-citationThe emerging role of fumarate as an oncometabolite
Yang, M., Soga, T., Pollard, P. J., & Adam, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00085 · Cited by 189
Bayley, J.-P., Launonen, V., & Tomlinson, I. P. (2008) · BMC Medical Genetics · doi:10.1186/1471-2350-9-20 · Cited by 162
Self-citationGardie, B., Remenieras, A., Kattygnarath, D., Bombled, J., Lefèvre, S.-H., Perrier-Trudova, V., Rustin, P., Barrois, M., Slama, A., Avril, M., et al. (2011) · Journal of Medical Genetics · doi:10.1136/jmg.2010.085068 · Cited by 160
Self-citationHereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics
Lehtonen, H. J. (2011) · Familial Cancer · doi:10.1007/s10689-011-9428-z · Cited by 160
Stewart, L., Glenn, G. M., Stratton, P., Goldstein, A. M., Merino, M. J., Tucker, M. A., Linehan, W. M., & Toro, J. R. (2008) · Archives of Dermatology · doi:10.1001/archdermatol.2008.517 · Cited by 111
Self-citationExploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC
Yamasaki, T., Tran, T. A. T., Öz, O. K., Raj, G. V., Schwarz, R. E., DeBerardinis, R. J., Zhang, X., & Brugarolas, J. (2011) · Nature Reviews Urology · doi:10.1038/nrurol.2010.234 · Cited by 58
Alrashdi, I., Levine, S., Paterson, J., Saxena, R., Patel, S. R., Depani, S., Hargrave, D. R., Pritchard‐Jones, K., & Hodgson, S. V. (2009) · Familial Cancer · doi:10.1007/s10689-009-9306-0 · Cited by 57
Alrefae, M., Wong, N., Patenaude, F., Bégin, L. R., & Foulkes, W. D. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0773 · Cited by 55
Management of von Hippel–Lindau-associated kidney cancer
Grubb, R. L., Choyke, P. L., Pinto, P. A., Linehan, W. M., & Walther, M. M. (2005) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0179 · Cited by 52
Self-citationTargeted therapeutic strategies for the management of renal cell carcinoma
Singer, E. A., Gupta, G. N., & Srinivasan, R. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328351c646 · Cited by 52
Familial multiple cutaneous and uterine leiomyomas associated with papillary renal cell cancer
Chan, I., Wong, T., Martı́nez-Mir, A., Christiano, A. M., & McGrath, J. A. (2005) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2004.01675.x · Cited by 52
Conventional renal cancer in a patient with fumarate hydratase mutation
Lehtonen, H. J., Blanco, I., Piulats, J. M., Herva, R., Launonen, V., & Aaltonen, L. A. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.10.011 · Cited by 50
van Spaendonck‐Zwarts, K. Y., Badeloe, S., Oosting, S. F., Hovenga, S., Semmelink, H. J. F., van Moorselaar, R. J. A., van Waesberghe, J. H., Mensenkamp, A. R., & Menko, F. H. (2011) · Familial Cancer · doi:10.1007/s10689-011-9491-5 · Cited by 37
Self-citationAhvenainen, T., Lehtonen, H. J., Lehtonen, R., Vahteristo, P., Aittomäki, K., Baynam, G. S., Dommering, C. J., Eng, C., Gruber, S. B., Grönberg, H., et al. (2008) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2008.01.010 · Cited by 33
Self-citationChuang, G. S., Martı́nez-Mir, A., Engler, D. E., Gmyrek, R., Zlotogorski, A., & Christiano, A. M. (2005) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2005.01977.x · Cited by 32
No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome
Vahteristo, P., Koski, T. A., Näätsaari, L., Kiuru, M. H., Karhu, A., Herva, R., Sallinen, S., Kuismin, O., Björck, E., Richard, S., et al. (2009) · Familial Cancer · doi:10.1007/s10689-009-9312-2 · Cited by 29
Self-citationFamilial renal cancer as an indicator of hereditary leiomyomatosis and renal cell cancer syndrome
Raymond, V. M., Herron, C. M., Giordano, T. J., & Gruber, S. B. (2011) · Familial Cancer · doi:10.1007/s10689-011-9485-3 · Cited by 21
Kuwada, M., Chihara, Y., Lou, Y., Torimoto, K., Kagebayashi, Y., Tamura, K., Shuin, T., Fujimoto, K., Kuniyasu, H., & Samma, S. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-203 · Cited by 16
Rongioletti, F., Fausti, V., Ferrando, B., Parodi, A., Mandich, P., & Pasini, B. (2010) · Dermatology · doi:10.1159/000321336 · Cited by 15
Defining an Individualized Treatment Strategy for Metastatic Renal Cancer
Hu, B. R., Lara, P. N., & Evans, C. P. (2012) · Urologic Clinics of North America · doi:10.1016/j.ucl.2012.02.002 · Cited by 13
Behnes, C. L., Schlegel, C., Shoukier, M., Magiera, I., Henschke, F., Schwarz, A., Bremmer, F., & Loertzer, H. (2013) · BMC Urology · doi:10.1186/1471-2490-13-3 · Cited by 5
Cutaneous papules, uterine fibroids, and renal cell cancer: one family's tale
Önder, M., Glenn, G. M., Adışen, E., Keseroğlu, Ö., Şahin, S., Ataoğlu, Ö., Akkaya, B., & Toro, J. R. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61499-9 · Cited by 5
Cited by
Epidemiology of Renal Cell Carcinoma: 2022 Update
Bukavina, L., Bensalah, K., Bray, F., Carlo, M., Challacombe, B., Karam, J. A., Kassouf, W., Mitchell, T., Montironi, R., O'Brien, T., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.08.019 · Cited by 775
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Motzer, R. J., Jonasch, E., Agarwal, N., Alva, A., Baine, M., Beckermann, K., Carlo, M. I., Choueiri, T. K., Costello, B. A., Derweesh, I. H., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0001 · Cited by 667
The Metabolic Basis of Kidney Cancer
Linehan, W. M., Schmidt, L. S., Crooks, D. R., Wei, D., Srinivasan, R., Lang, M., & Ricketts, C. J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1354 · Cited by 306
Self-citationTrpkov, K., Hes, O., Williamson, S. R., Adeniran, A. J., Agaimy, A., Alaghehbandan, R., Amin, M. B., Argani, P., Chen, Y.-B., Cheng, L., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00779-w · Cited by 258
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021: Featured Updates to the NCCN Guidelines
Motzer, R. J., Jonasch, E., Boyle, S., Carlo, M. I., Manley, B., Agarwal, N., Alva, A., Beckermann, K., Choueiri, T. K., Costello, B. A., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0043 · Cited by 255
Metadata
- Authors
- Menko, F. H., Maher, E. R., Schmidt, L. S., Middelton, L. A., Aittomäki, K., Tomlinson, I., Richard, S., & Linehan, W. M.
- Venue
- Familial Cancer
- Published
- 2014-07-11
- Volume
- 13
- Issue
- 4
- Pages
- 637-644
- ISSN
- 1389-9600 (ISSN-L)
- 1573-7292
- OpenAlex
- W2143929280
- Cited by
- 356
- References
- 48
- FWCI
- 13.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.